Market Research Logo

Global PNH & aHUS Market: Industry Analysis & Outlook (2017-2021)

Global PNH & aHUS Market: Industry Analysis & Outlook (2017-2021)

PNH and aHUS, both are extremely rare and genetic diseases. Due to PNH, destruction of red blood cells of a person occurs quite sooner than it should. It is an acquired hematopoietic stem cell disorder. Hematopoietic stem cells are developed in bone marrow and eventually turn into red blood cells, white blood cells and platelets. A person with PNH has some defected hematopoietic cells which create defective red blood cells. These defective cells are highly susceptible to premature destruction by the complement system. aHUS is a disorders in which blood clots are formed in small blood vessels throughout the body. TMA can lead to heart stroke, attack, kidney failure and death. Soliris is the only drug treatment available in the market for treating these diseases.

Regionally, Europe held the largest share in the global PNH drug market and the U.S. dominated the global aHUS drug market, supported by favorable reimbursement policies In terms of patient population, Asia-pacific region had the highest number of PNH and aHUS patients. With the increasing technological advancements in diagnosis techniques of PNH and aHUS, the number of diagnosed patients is likely to grow globally.

The global PNH and aHUS market is expected to grow in future due to prolonged orphan drug market exclusivity, attractive orphan drug policies, increasing pharmaceutical R&D expenditure, rising health care expenditure. Key trends of this market include progressing drugs under pipeline, increasing prevalence of blood and bone marrow related disorders and favorable reimbursement policies. However, there are some factors which can hinder the market growth including high costs of drugs and associated risks.

The report “Global PNH and aHUS Market: Industry Analysis & Outlook (2017-2021)” by Koncept Analytics provides an extensive research and detailed analysis of the present market along with future outlook. The report discusses the major growth drivers and challenges of the market, covering the U.S., Europe and Asia-Pacific region along with the global market. The report profiles the key players of the market including Alexion Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc, Omeros Corporation and RA Pharmaceuticals.


1. Overview
1.1 Introduction to PNH
1.2 Symptoms and Diagnosis of PNH
1.3 Treatment of PNH
1.4 Introduction to aHUS
1.5 Symptoms and Diagnosis of aHUS
1.6 Treatment of aHUS
2. Global PNH and aHUS Market
2.1 PNH Patient Population
Table 1: Global PNH Patient Population Forecast (2016-2021)
2.2 PNH Drug Market Value Forecast
Table 2: Global PNH Drug Market Value Forecast (2016-2021)
2.3 PNH Drug Market by Type
Table 3: Global PNH Drug Market by Type (2016/2021)
2.4 PNH Drug Market by Region
Table 4: Global PNH Drug Market Value by Region (2016)
2.5 aHUS Patient Population Forecast
Table 5: Global aHUS Patient Population Forecast (2016-2021)
2.6 aHUS Drug Market Value Forecast
Table 6: Global aHUS Drug Market Value Forecast (2016-2021)
2.7 aHUS Drug Market by Type
Table 7: Global aHUS Drug Market by Type (2016/2021)
2.8 aHUS Drug Market by Region
Table 8: Global aHUS Drug Market Value by Region (2016)
3. Regional Market
3.1 The U.S.
3.1.1 The U.S. PNH Patient Population Forecast
Table 9: The U.S. PNH Patient Population Forecast (2016-2021)
3.1.2 The U.S. PNH Drug Market Value Forecast
Table 10: The U.S. PNH Drug Market Value Forecast (2016-2021)
3.1.3 The U.S. aHUS Patient Population Forecast
Table 11: The U.S. aHUS Patient Population Forecast (2016-2021)
3.1.4 The U.S. aHUS Drug Market Value Forecast
Table 12: The U.S. aHUS Drug Market Value Forecast (2016-2021)
3.2 Europe
3.2.1 Europe PNH Patient Population Forecast
Table 13: Europe PNH Patient Population Forecast (2016-2021)
3.2.2 Europe PNH Drug Market Value Forecast
Table 14: Europe PNH Drug Market Value Forecast (2016-2021)
3.2.3 Europe aHUS Patient Population Forecast
Table 15: Europe aHUS Patient Population Forecast (2016-2021)
3.2.4 Europe aHUS Drug Market Value Forecast
Table 16: Europe aHUS Drug Market Value Forecast (2016-2021)
3.3 Asia-Pacific
3.3.1 Asia-Pacific PNH Population Forecast
Table 17: Asia-Pacific PNH Population Forecast (2016-2021)
3.3.2 Asia-Pacific PNH Drug Market- Soliris Sales Value Forecast
Table 18: Asia-Pacific PNH Drug Market- Soliris Sales Value Forecast (2016-2021)
3.3.3 Asia-Pacific aHUS Patient Population Forecast
Table 19: Asia-Pacific aHUS Patient Population Forecast (2016-2021)
3.3.4 Asia-Pacific aHUS Drug Market- Soliris Sales Value Forecast
Table 20: Asia-Pacific aHUS Drug Market- Soliris Sales Value Forecast (2016-2021)
4. Market Dynamics
4.1 Growth Drivers
4.1.1 Prolonged Orphan Drug Market Exclusivity
Table 21: Orphan Drug Market Exclusivity
4.1.2 Attractive Orphan Drug Development Policies
Table 22: Orphan Drug Policies by Region
4.1.3 Increasing Pharmaceutical R&D Spending
Table 23: Global Pharmaceutical R&D Spending (2012-2016)
4.1.4 Rising Healthcare Expenditure
Table 24: Global Healthcare Expenditure per Capita (2012-2016)
4.2 Key Trends & Developments
4.2.1 Progressing Drugs under Pipeline
Table 25: Drugs under Development for PNH and aHUS (2016)
4.2.2 Favorable Reimbursement Policies
4.2.3 Increasing Prevalence of Blood and Bone Marrow Related Disorders
4.3 Challenges
4.3.1 High Prices of Drugs
4.3.2 Other Associated Risks
5. Competitive Landscape
5.1 Global Market
5.1.1 Revenue Comparison of Key Companies
Table 26: Revenue Comparison of Key Companies (2016)
5.1.2 Market Cap Comparison of Key Companies
Table 27: Market Cap Comparison of Key Companies (2016)
6. Company Profiles
6.1 Alexion Pharmaceuticals Inc.
6.1.1 Business Overview
Table 28: Alexion Pharmaceuticals Inc. Sales by Product (2016)
6.1.2 Financial Overview
Table 29: Alexion Pharmaceuticals Inc. Total Revenue & Net Income (2012-2016)
6.1.3 Business Strategies
Table 30: Alexion Pharmaceuticals Inc. R&D Expenditure (2014-2016)
6.2 Alnylam Pharmaceuticals, Inc.
6.2.1 Business Overview
Table 31: Alnylam Pharmaceuticals, Inc. Drug Pipeline (2016)
6.2.2 Financial Overview
Table 32: Alnylam Pharmaceuticals, Inc. Net Revenue & Net Loss (2012-2016)
6.2.3 Business StrategiesTable 33: Alnylam Pharmaceuticals, Inc. R&D Expenditure (2014-2016)
6.3 Omeros Corporation
6.3.1 Business Overview
6.3.2 Financial Overview
Table 34: Omeros Corporation Revenue and Net Loss (2012-2016)
6.3.3 Business Strategies
Table 35: Omeros Corporation R&D Expenditure (2014-2016)
Table 36: Omeros Corporation Clinical Drug Development Programs (2016)
6.4 RA Pharmaceuticals Inc.
6.4.1 Business Overview
Table 37: RA Pharmaceuticals Inc. Drug Pipeline (2016)
6.4.2 Financial Overview
Table 38: RA Pharmaceuticals Inc. Revenue & Net Loss (2012-2016)
6.4.3 Business Strategies
Table 39: RA Pharmaceuticals Inc. R&D Expenditure (2014-2016)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report